Epidemiology

Family history of cancer and risk of paediatric and young adult’s testicular cancer: A Norwegian cohort study

Ruby Del Risco Kollerud1,2, Ellen Ruud3,4, Hege S. Haugnes5,6, Lisa A. Cannon-Albright7, Magne Thoresen6, Per Nafstad1, Ljiljana Vlatkovic9, Karl Gerhard Blaasaas10, Øyvind Naess1 and Bjørgulf Claussen1

BACKGROUND: The aim of this study was to examine the association of a family history of cancer with the risk of testicular cancer in young adults.

METHODS: This is a prospective cohort study including 1,974,287 males born 1951–2015, of whom 2686 were diagnosed with TC before the age of 30.

RESULTS: A history of TC in male relatives was significantly associated with a diagnosis of TC among children and young adults, including brothers (6.3-fold), sons (4.7-fold), fathers (4.4-fold), paternal uncles (2.0-fold) and maternal uncles (1.9-fold). Individuals with a father diagnosed with a carcinoma or sarcoma showed an elevated risk (1.1-fold and 1.8-fold, respectively). A family history of mesothelioma was positively associated with a risk of TC (father (2.8-fold), mother (4.6-fold) and maternal uncles and aunt (4.4-fold)). Elevated risks were also observed when siblings were diagnosed with malignant melanoma (1.4-fold). The risk of TC was also increased when fathers (11.1-fold), paternal (4.9-fold) and maternal uncles and aunts (4.6-fold) were diagnosed with malignant neuroepithelial-tumours.

CONCLUSION: We found an increased risk of TC among children and young adults with a family history of TC, carcinoma, mesothelioma, sarcoma, malignant melanoma and malignant neuroepithelial tumours. Hereditary cancer syndromes might underlie some of the associations reported in this study.

British Journal of Cancer (2019) 120:1007–1014; https://doi.org/10.1038/s41416-019-0445-2

BACKGROUND
Germ-cell testicular cancer (TC) is the most common form of cancer in young males in industrialised countries. The global incidence of TC has more than doubled over the past 40 years.1 Males born around 1943 and around 1968 in the Nordic countries are at lower risk of TC than men born before and after each of these dates, suggesting a birth-cohort effect in the incidence of TC.2

The majority of TC derives from germ cells and can be divided into two major histologic types: pure classic seminoma and non-seminomatous germ cell tumours. These are believed to originate from a common precursor, the germ cell neoplasia in situ (GCNIS).3

The aetiology of TC remains unknown. Rapid increases in TC incidence highlight the importance of investigating risk factors involved in the development of this cancer. The strongest risk factors are a family history of the disorder, a previously diagnosed TC, and cryptorchism.4–9 Prenatal and postnatal exposure to certain persistent environmental chemicals classified as endocrine disruptors have been reported to be associated with the risk of testicular cancer. However, the evidence is limited.10 Socio-economic differences in the incidence rates of TC have also been reported in the Nordic countries.11 Cancer in children and young adults generally has more underlying genetic causes compared to cancer in older adults, who have decreased DNA repair capability and longer environmental exposure. In order to identify a young population with a possible inherited cancer predisposition syndrome, an accurate family history integrating information about the site of the origin of the cancer, as well as tumour characteristics such as cancer morphology in relatives, is essential. The most common malignancies associated with hereditary cancer syndromes include morphological types such as sarcomas, carcinomas, epitheliomas, glioblastomas, malignant melanomas and endocrine tumours, as seen in the Li-Fraumeni syndrome, Lynch syndrome, cutaneous malignant melanoma syndrome and multiple endocrine neoplasia.12 Consequently, we hypothesise that children and young adults with TC more frequently have relatives with common malignancies associated with hereditary cancer syndromes compared to children without TC.

Previous studies into familial clustering of cancer have typically used organ-specific site classification rather than histological...
subtypes to examine the risk of TC. Insight into the association of familial clustering of cancers with TC, based on morphological cancer groups, might contribute to the identification of individuals at increased risk of developing the disorder, and might also increase our understanding of this cancer.

The aim of this study was to examine the association of a family history of cancer, evaluating the impact of both morphological groups as well as organ of origin, with the risk of TC in children and young adults. We took advantage of the close to complete population-based registries in Norway that contain uniform and continuously updated information on childbirth, familial relationship, cancer incidence and vital status.

MATERIALS AND METHODS

Study population

All males born in Norway from 1951 to 2015 were included in the study. Information on these individuals and their first-degree relatives, uncles and aunts was obtained from the Central Population Register of Norway which has information on the relationship between each individual and his/her relatives. Information on first degree relatives for each individual is almost complete for individuals born in Norway since 1950. We identified cancer among all included males and their relatives through linkage to the Norwegian Cancer Registry using Norwegian personal identification numbers.

Cases or index persons were all males registered in the Norwegian Cancer Registry who had been diagnosed with TC before the age of 30 years between 1951 and 2015. TC was classified into seminomas and non-seminomas using the International Statistical Classification of Diseases for Oncology (ICDO-3) and topography (C62). Unclassified TC (n = 271) was excluded from the analyses.

Cancer among relatives

Morphological groups were classified according to the World Health Organization's morphologic classification of human cancer into seven main groups: carcinomas, sarcomas, mesotheliomas, tumours of the haematopoietic and lymphoid tissues, Kaposi sarcomas, other specified cancer types, and unspecified types of cancer (Supplementary Table 1). Kaposi sarcomas, some unspecified types of cancer and some morphological subgroups were excluded from the analysis due to small sample sizes.

A separate analysis of the major morphological groups was also conducted using the organ of origin of the cancer in relatives. Analyses of cancer were conducted among relatives based on the anatomic site (topography) of the body in which the cancer originated using the International Statistical Classification of Diseases and related health problems (ICD-10). To reduce the width of our confidence intervals and to increase precision, ICD-10 codes for which at least two relatives of the index persons diagnosed with cancer were identified were included. This strategy was applied to all the analyses. The following organs and codes were considered: Lip, oral cavity and pharynx (C00-C14), oesophagus (C15), stomach (C16), colon (C18), rectum (C20), pancreas (C25), lung (C34), skin (C43-C44), breast (C50), cervix uteri (C53), Corpus uteri(C54), ovary (C56), prostate (C61), kidney (C64), ureter (C66), bladder (C67) and thyroid (C73).

Other variables

Families might have different socioeconomic status and levels of environmental exposure that could potentially confound our findings. Models were adjusted for mother or father’s education. Adjustments for the number of family members were also made to account for the difference in family size. Information on parent’s educational level was obtained from Statistics Norway and was categorised into five subgroups according to the International Standard Classification of Education: primary education (<10 years), secondary education and tertiary vocational education (10–14 years), and higher education (equivalent to bachelor, master or PhD). To control for birth-cohort effects reported in other studies, adjustments were made for year of birth.

Statistical analysis

Cox proportional hazard regression was used to estimate the association between the incidence of cancer in relatives and risk of TC. Testicular cancer in a child or young adult was the dependent variable and cancer in relatives the explanatory variable. Age was used as time scale. The follow-up period for each child and young adult was from birth to the age of cancer diagnosis, with censoring at the age of 30 years, death, emigration or end of study. All analyses were adjusted for number of relatives (continuous variable), according to which relative was examined. The risk of TC according to the relationship of the cancer-affected relatives was examined to determine whether there were differences in risk according to kinship. The hazard ratio (HR) and 95% confidence intervals (CI) for morphological types are presented separately for father, mother, siblings, paternal uncles and aunts, and maternal uncles and aunts. Risk estimates for cancer by ICD-10 subtypes included groups of relatives: parents, siblings and both paternal and maternal uncles and aunts. These last analyses were conducted separately for seminomas and non-seminomas. Due to the limited number of cases diagnosed with TC before the age of 15 years, data for the whole population were presented. Offspring of the index person were not included because of the low number of cancer cases found in this group. The proportional hazards assumption was verified by plotting Schoenfeld residuals.

All analyses were performed using SPSS version 25 (IBM, Armonk, NY, USA).

RESULTS

A total of 1,974,287 males born between 1951 and 2015 were followed for risk of TC. During this period 2686 index persons were diagnosed with TC (Table 1). The majority of cases were diagnosed with non-seminomas. Index persons diagnosed with seminomas were slightly older compared with non-seminomas (Table 1; Fig. 1). Most of the study population had information on variables included in the analysis for mother (99.4%) and father (98.1%). The associations between a family history of cancer and risk of TC were similar before and after adjustment for covariates; adjusted results are reported.

Cancer family history across morphological groups

Associations of risk of TC with a family history of cancer (all cancer subtypes) were observed for multiple relationships and morphological groups (Table 2). Statistically significant associations were observed for index persons where fathers and maternal uncles and aunts were diagnosed with carcinomas HR = 1.11 (1.00–1.23) and HR = 1.15 (1.02–1.30), respectively, particularly the subtype adenocarcinoma. The risk of TC was also elevated when fathers were diagnosed with sarcomas HR = 1.81 (1.10–2.96).

A family history of mesothelioma was associated with the risk of TC. The risk increased when father, mother or maternal uncles and aunts of index persons were diagnosed with mesothelioma HR = 2.77 (1.38–5.56), HR = 4.62 (1.16–18.50) and HR = 4.44 (1.85–10.70), respectively.

Overall, the risk of TC was associated with a family history of TC in male relatives (Fig. 2). The highest risk was noted among index persons with a brother with TC (6-fold increased risk), followed by individuals with a son or father diagnosed with testis cancer (4-fold increased risk). Statistically significant results were also observed for paternal and maternal uncles (Fig. 2). The highest risk was observed among index persons with brothers diagnosed with TC type non-seminomas HR = 8.24 (6.15–11.04).
siblings the risk was also elevated for malignant melanoma HR = 1.45 (1.01–2.06).

A positive family history of malignant melanoma was also associated with an increased risk of TC. The elevated risk was observed among index person with an affected father and paternal and maternal uncles and aunts HR = 11.15 (2.78–44.57); HR = 4.92 (1.23–19.70) and HR = 4.62 (1.15–18.50), respectively.

Table 1. Descriptive characteristics of a population-based cohort of male children and young adults <30 years born in Norway during 1951–2015

| Variable                        | Cases | Non-cases |
|---------------------------------|-------|-----------|
|                                 | No.   | %         | No.   | %         |
| Total                           | 2686  | 0.1       | 1,971,601 | 99.9     |
| **Tumour histology**            |       |           |       |           |
| Seminoma                        | 761   | 28.3      |       |           |
| Non-seminoma                    | 1654  | 61.6      |       |           |
| Unclassified                    | 271   | 10.1      |       |           |
| **Mean age at cancer diagnosis (SD)** |       |           |       |           |
| All cases                       | 24    | (4.9)     |       |           |
| Seminoma                        | 26    | (3.1)     |       |           |
| Non-seminoma                    | 23    | (5.2)     |       |           |
| **Father’s education (years)**  |       |           |       |           |
| <10                             | 919   | 34.2      | 267,137 | 28.8      |
| 10–14                           | 1264  | 47.1      | 700,203 | 35.5      |
| >14                             | 474   | 17.6      | 395,912 | 20.1      |
| Missing                         | 29    | 1.1       | 308,349 | 15.6      |
| **Mother’s education (years)**  |       |           |       |           |
| <10                             | 726   | 27.0      | 475,844 | 24.1      |
| 10–14                           | 1332  | 49.6      | 783,268 | 39.7      |
| >14                             | 560   | 20.8      | 377,921 | 19.2      |
| Missing                         | 68    | 2.5       | 334,568 | 17.0      |
| **Mean age at cancer diagnosis (SD)** |       |           |       |           |
| Father                          | 668   | 64.1      | 338,567 | 66.1      |
|                                |       | (12.4)    |         | (13.1)    |
| Mother                          | 538   | 61.2      | 288,954 | 61.7      |
|                                |       | (13.9)    |         | (14.9)    |
| Brothers                        | 166   | 39.7      | 64,941  | 47.1      |
|                                |       | (16.0)    |         | (16.9)    |
| Sisters                         | 121   | 43.4      | 70,820  | 45.4      |
|                                |       | (13.5)    |         | (14.3)    |
| Sons                            | 14    | 17.6      | 5261    | 18.6      |
|                                |       | (8.5)     |         | (11.5)    |
| Daughters                       | 8     | 14.0      | 5102    | 20.8      |
|                                |       | (10.8)    |         | (12.0)    |
| Paternal uncles                 | 221   | 59.8      | 120,627 | 57.9      |
|                                |       | (14.3)    |         | (15.3)    |
| Paternal aunts                  | 194   | 54.8      | 109,509 | 53.2      |
|                                |       | (13.5)    |         | (14.4)    |
| Maternal uncles                 | 240   | 57.3      | 107,971 | 56.3      |
|                                |       | (13.5)    |         | (15.6)    |
| Maternal aunts                  | 204   | 54.7      | 103,467 | 52.1      |
|                                |       | (12.0)    |         | (14.4)    |

SD standard deviation

Cancer family history of cancer by cancer site

The risk of developing TC among index persons increased overall when parents were diagnosed with squamous cell carcinoma of the lung (Table 3) and significantly increased for non-seminomas HR = 1.58 (1.01–2.46), but not significantly for seminomas. A maternal diagnosis of cervical cancer increased the risk of seminoma among index persons HR 1.92 (1.00–3.72). Index persons with a sister diagnosed with breast cancer of type adenocarcinoma had an elevated risk of TC HR = 2.00 (1.24–3.21).

A positive family history of urothelial cancer among uncles and aunts was associated with an elevated risk of TC in index persons HR = 3.15 (1.01–9.81) (Supplementary Table 2). Cancer of other organs showing elevated risk of TC was found among index persons with uncles and aunts diagnosed with stomach cancer of type adenocarcinoma HR = 2.38 (1.14–4.95) (Supplementary Table 2).

Elevated risk was also observed in index persons with siblings affected by other types of cancer, excluding carcinomas HR = 1.87 (1.59–2.21).

**DISCUSSION**

This population-based cohort study suggests that there is a significantly elevated risk of TC among individuals with a family history of cancer that extends beyond TC. Elevated risks were observed for family history of carcinoma, mesothelioma, sarcomas, testicular germ tumours, malignant melanoma and malignant neuroepithelial tumours. Such findings of elevated risks among these morphological groups, with the exception of germ cell tumours and melanoma in a large population study, have not been previously reported.

An increased risk of developing TC in males with first-degree relatives diagnosed with TC is consistent with previous studies. We also found an elevated risk of TC among index persons with paternal and maternal uncles diagnosed with TC (Fig. 2). A recent study reported elevated risk of TC with a family history of breast cancer, melanoma, lung cancer and cancer in the central nervous system.

Human testicular cancer susceptibility genes have not yet been identified. The putative gene mapped to Xq27 is postulated to confer an increased risk of TC as well as cryptorchism. Cancer is recognised as a disease that result from gradual accumulation of somatic mutations in the genome.21 The mutation frequency in the whole genome between generations of humans (parent to child) is about 70 new mutations per generation.22 Carcinomas, however, have much higher mutation frequencies.23 The high mutation frequencies in carcinomas reflect the genome instability characteristic of cancer. New results from the Cancer Genome Atlas Research Project have identified genetic mutations that are common among 12 different types of cancer, including carcinomas, adenocarcinomas and melanomas. This reflects the growing understanding that tumours can be defined by their underlying biology rather than their location in the body.24 Our results provide evidence of an increased familial risk of TC associated with a general family history of cancer; especially perhaps subtypes squamous cell carcinoma, urothelial carcinoma and adenocarcinoma. In an analysis of carcinomas by organ site, elevated risks were found for the lung, breast, cervix, uterus and stomach. Squamous cell carcinoma of the lung accounts for around 30% of all lung cancer. Although this histological subtype has a stronger association with smoking than any other type of lung cancer, family history and exposure to asbestos or radon are also risk factors for this type of cancer.

The association between a family history of mesothelioma and TC in young TC patients has not been previously reported. A particularly striking finding in the present study was the significant increase in the risk of TC among index persons with parents and uncles and aunts with mesothelioma. The increased risk was
Family history of cancer and risk of paediatric and young adult's…
R Del Risco Kollerud et al.

Fig. 1  Age distribution of children and young adults <30 years born in Norway during 1951–2015 and who were diagnosed with testicular cancer in the same period

Table 2. Adjusted hazard ratios (95% confidence interval) for family history of cancers by morphologic groups and risk of testis cancer among children and young adults <30 years born in Norway during 1951–2015

| Morphologic groups in relatives | Father | Mother | Siblings | Fathers siblings | Mothers siblings |
|-------------------------------|--------|--------|----------|-----------------|-----------------|
| Carcinomas                    | 496    | 416    | 119      | 311             | 343             |
| Squamous cell carcinoma       | 1.11 (1.00–1.23) | 1.10 (0.98–1.22) | 0.91 (0.75–1.11) | 0.98 (0.86–1.11) | 1.15 (1.02–1.30) |
| Urothelial carcinoma          | 0.15 (0.90–1.47) | 1.14 (0.87–1.50) | 0.91 (0.55–1.49) | 0.63 (0.43–0.93) | 1.17 (0.87–1.57) |
| Adenocarcinoma                | 1.06 (0.77–1.46) | 1.29 (0.76–2.19) | 0.76 (0.29–2.04) | 0.87 (0.52–1.45) | 1.11 (0.70–1.77) |
| Other specific carcinomas     | 1.13 (1.01–1.27) | 1.04 (0.92–1.18) | 1.00 (0.81–1.23) | 1.04 (0.91–1.20) | 1.20 (1.05–1.37) |
| Neuroendocrine carcinoma      | 1.28 (0.91–1.79) | 1.32 (0.93–1.89) | 0.64 (0.29–1.44) | 0.90 (0.57–1.41) | 1.18 (0.79–1.75) |
| Sarcomas and soft tissue tumours | 1.81 (1.10–2.96) | 1.36 (0.77–2.39) | 0.95 (0.47–1.90) | 1.11 (0.61–2.01) | 0.60 (0.27–1.34) |
| Mesothelioma                  | 2.77 (1.38–5.56) | 1.36 (0.77–2.39) | – NC         | – NC             | 4.44 (1.85–10.70) |
| Tumours of hematopoietic and lymphoid tissues | 0.99 (0.75–1.31) | 1.00 (0.72–1.38) | 1.00 (0.66–1.48) | 1.17 (0.87–1.58) | 4.13 (0.83–1.54) |
| Myeloid                       | 0.57 (0.24–1.38) | 0.74 (0.31–1.77) | 0.45 (0.11–1.82) | 0.60 (0.23–1.61) | 1.19 (0.60–2.39) |
| B-cell neoplasms              | 1.17 (0.83–1.64) | 1.19 (0.80–1.75) | 1.58 (0.95–2.62) | 1.29 (0.89–1.87) | 0.99 (0.65–1.53) |
| Non-Hodgkin lymphoma          | 0.97 (0.49–1.53) | 1.49 (0.93–2.41) | 1.45 (0.72–2.90) | 1.41 (0.88–2.28) | 1.04 (0.59–1.83) |
| Multiple myeloma and other plasma cell | 1.32 (0.75–2.33) | 0.77 (0.32–1.85) | 1.59 (0.51–4.95) | 1.23 (0.59–2.58) | 0.93 (0.39–2.25) |
| Hodgkin lymphoma              | 1.42 (0.53–3.80) | – NC             | 0.46 (0.12–1.86) | 1.30 (0.49–3.48) | 0.90 (0.29–2.79) |
| Malignant melanoma            | 0.66 (0.43–1.01) | 1.08 (0.77–1.50) | 1.14 (0.59–2.19) | 0.57 (0.24–1.38) | 0.35 (0.11–1.07) |
| Seminoma (C62)                | 4.45 (2.92–6.77) | – NC             | 25 3.75 (2.52–5.56) | 8 1.89 (0.94–3.78) | 1.20 (0.54–2.67) |
| Non-seminoma (C62)            | 10 4.50 (2.42–8.37) | – NC             | 46 8.24 (6.15–11.04) | 6 2.37 (1.06–5.30) | 8 2.87 (1.43–5.76) |
| Gliomas (C71)                 | 4 0.41 (0.15–1.10) | 6 0.90 (0.40–2.01) | 9 1.14 (0.59–2.19) | 5 0.57 (0.24–1.38) | 3 0.35 (0.11–1.07) |
| Meningiomas                   | 4 1.12 (0.42–2.99) | 11 1.12 (0.62–2.02) | 4 1.04 (0.39–2.77) | 4 0.61 (0.24–1.64) | 5 0.79 (0.33–1.90) |
| Malignant neuroepithelial tumours | 2 11.15 (2.78–44.57) | – NC             | 2 1.61 (0.40–6.45) | 2 4.92 (1.23–19.70) | 2 4.62 (1.15–18.50) |

The model was adjusted for child’s birth year and number of relatives according to type analysis. The model for parents and sibling was also adjusted for mother or father’s education.

Cases: number of cancer cases with relatives affected
NC: children with <2 relatives diagnosed with cancer estimates were no calculated. We included morphologic groups were we find at least 2 relatives of the index persons diagnosed with cancer.

The bold values mean Hazard ratios statistically significant at 5% level.
Family history of cancer and risk of paediatric and young adult’s…
R Del Risco Kollerud et al.

Retinoblastoma, neuroblastoma, ganglioglioma and neuroepithelioma are among the most common neuro-epitheliomatous neoplasms. These cancers are associated with several hereditary cancer syndromes such as hereditary retinoblastoma, where sarcomas are the most frequent second cancer. Additional cancers found in this syndrome include leukaemia, lymphoma, melanoma, lung and bladder cancer.14 Neuroblastoma is also a feature of neurofibromatosis type 1 and the Beckwith-Wiedemann syndrome.

The results of the present study taken together with the results of other studies suggest that hereditary cancer syndromes could be involved in a predisposition to TC in young males. However, these findings do not exclude a possible influence of shared environmental factors among family members. Further research is needed to clarify the molecular genetic basis of testicular cancer and to identify potential susceptibility genes playing a role in the aetiology of the disease. More research is also needed to assess the possible interplay between environmental factors and genetic susceptibility in cancer causation. A better understanding of testicular cancer predisposition and biology will lead to further refinements in the clinical management of the disease, especially regarding identification of individuals of higher risk.

The present study has several strengths. It is based on all births in Norway from 1951 to 2015. Thus, bias caused by a skewed study sample is unlikely. Information on the variables of interest was obtained from the linkage of national population-based registers (removing ascertainment and recall bias), and the high quality of cancer case registration permitted a complete follow-up of the study population. Data from the Norwegian Cancer Registry is considered reasonably accurate and close-to-complete.41

The study also has some limitations. The present study is a registry-based study, with no access to biological samples for genetic analyses. Information on cancer risk among parents at a young age in the first birth cohort period was not available and could introduce bias by left truncation. The follow-up for cancer among relatives was until 2015. This could introduce bias. Parents and other first-degree relatives of children and young adults are often young, and cancer may not have developed yet. As noted, the number of cancer cases observed among the offspring of index cases was insufficient to include these relationships in the study. However, both of these sources of bias would lead to an underestimation of the actual cancer risk. Although this is a large cohort study some of these associations were based on small numbers that might lead to some false positive results. Thus, the results are best considered together with those from similar studies. The study is based on children from Norway, primarily a white population. It is unclear whether these data can be generalised to non-Caucasian populations. Finally, this study should be considered to be hypothesis generating due to the high number of hypotheses considered.

CONCLUSION
We found significantly elevated risks of TC among children and young adults with a family history of testicular cancer, carcinomas, mesothelioma, sarcomas, malignant melanoma and malignant neuroepithelial tumours. Our results show that many of the cancers identified in the relatives of TC cases are found to be associated with the spectrum of several known cancer syndromes, such as cancers observed in BAP1 tumour predisposition syndrome, Li-Fraumeni syndrome, Familial Melanoma Syndrome, neurofibromatosis and hereditary retinoblastoma. Other syndromes cannot be excluded. However, the present study contains multiple comparisons and the results must be interpreted with caution. Further research into the genetic and environmental interactions associated with the risk of TC is critically important.
| Type carcinoma in relatives | Parents | Siblings |
|-----------------------------|---------|----------|
|                             | All cases | Seminoma | Non-seminoma | All cases | Seminoma | Non-seminoma |
|                             | n | HR (95% CI) | n | HR (95% CI) | n | HR (95% CI) | n | HR (95% CI) | n | HR (95% CI) | n | HR (95% CI) |
| Squamous cell carcinoma     |     |           |     |           |     |           |     |           |     |           |     |           |
| Lips, oral cavity and pharynx | 14 | 0.93 (0.55–1.57) | 4 | 0.93 (0.35–2.48) | 10 | 1.14 (0.61–2.12) | – | NC | – | NC | – | NC |
| Lung                        | 32 | **1.41 (1.00–2.00)** | 7 | 1.09 (0.51–2.29) | 20 | **1.58 (1.01–2.46)** | – | NC | – | NC | – | NC |
| Skin                        | 35 | 1.00 (0.72–1.42) | 9 | 0.89 (0.46–1.72) | 23 | 1.19 (0.78–1.79) | 4 | 1.41 (0.53–3.77) | – | NC | – | NC |
| Cervix uteri                | 21 | 1.26 (0.82–1.94) | 9 | **1.92 (1.00–3.72)** | 10 | 1.01 (0.54–1.88) | 6 | 0.89 (0.40–1.98) | 3 | 1.59 (0.51–4.94) | 3 | 0.78 (0.25–2.43) |
| Urothelial carcinoma        |     |           |     |           |     |           |     |           |     |           |     |           |
| Ureter                      | 2  | 1.48 (0.37–5.91) | – | NC | 2 | 2.69 (0.67–10.8) | – | NC | – | NC | – | NC |
| Bladder                     | 47 | 1.10 (0.83–1.48) | 10 | 0.82 (0.44–1.53) | 30 | 1.25 (0.87–1.79) | 4 | 0.86 (0.32–2.29) | – | NC | – | NC |
| Adenocarcinoma              |     |           |     |           |     |           |     |           |     |           |     |           |
| Oesophagus                  | 6  | 1.60 (0.72–3.56) | 2 | 1.84 (0.46–7.37) | 3 | 1.36 (0.44–4.43) | – | NC | – | NC | – | NC |
| Stomach                     | 26 | 1.12 (0.76–1.65) | 10 | 1.53 (0.82–2.87) | 12 | 0.93 (0.52–1.64) | – | NC | – | NC | – | NC |
| Colon                       | 91 | 1.10 (0.89–1.35) | 28 | 1.16 (0.79–1.70) | 50 | 1.05 (0.79–1.40) | 10 | 1.01 (0.54–1.88) | 2 | 0.73 (0.18–2.85) | 6 | 1.13 (0.51–2.53) |
| Rectum                      | 45 | 1.08 (0.88–1.34) | 15 | 1.25 (0.75–2.10) | 24 | 1.02 (0.68–1.52) | 9 | 1.50 (0.78–2.90) | 2 | 1.23 (0.31–4.93) | 5 | 1.55 (0.64–3.73) |
| Pancreas                    | 23 | 1.25 (0.83–1.90) | 4 | 0.75 (0.28–2.00) | 14 | 1.34 (0.79–2.27) | 2 | 0.89 (0.22–3.55) | – | NC | – | NC |
| Lung                        | 31 | 0.97 (0.68–1.38) | 8 | 0.86 (0.43–1.73) | 16 | 0.86 (0.53–1.42) | 5 | 1.08 (0.45–2.59) | 2 | 1.60 (0.40–6.45) | 2 | 0.81 (0.20–3.24) |
| Breast (female)             | 123 | 1.04 (0.87–1.25) | 27 | 0.78 (0.53–1.14) | 72 | 1.02 (0.81–1.30) | 42 | 1.28 (0.94–1.75) | 18 | **2.00 (1.24–3.21)** | 18 | 1.01 (0.63–1.60) |
| Cervix uteri                | 2  | 0.77 (0.19–3.08) | – | NC | 2 | 1.26 (0.31–5.04) | – | NC | – | NC | 0 | NC |
| Corpus uteri                | 21 | 0.92 (0.60–1.41) | 10 | 1.48 (0.79–2.77) | 6 | 0.46 (0.21–1.02) | – | NC | – | NC | – | NC |
| Ovary                       | 19 | 1.05 (0.67–1.66) | 4 | 0.76 (0.28–2.04) | 11 | 1.06 (0.59–1.92) | 4 | 1.09 (0.41–2.91) | 3 | 2.97 (0.95–8.99) | – | NC |
| Prostate                    | 179 | 1.14 (0.97–1.33) | 56 | 1.21 (0.92–1.60) | 98 | 1.08 (0.88–1.33) | 16 | 0.94 (0.57–1.54) | 5 | 1.09 (0.45–2.56) | 7 | 0.79 (0.37–1.67) |
| Kidney                      | 26 | 1.10 (0.75–1.62) | 7 | 1.03 (0.49–2.16) | 14 | 1.01 (0.60–1.72) | 3 | 0.59 (0.19–1.85) | – | NC | 2 | 0.73 (0.18–2.93) |
| Thyroid                     | 12 | 1.20 (0.71–2.20) | 4 | 1.45 (0.54–3.87) | 7 | 1.19 (0.57–2.49) | 3 | 0.68 (0.22–2.12) | – | NC | 2 | 0.80 (0.20–3.21) |
| No carcinomas               | 2399 | 0.88 (0.78–1.00) | 674 | 0.83 (0.66–1.05) | 1497 | 0.94 (0.80–1.11) | 158 | **1.87 (1.59–2.11)** | 44 | **1.85 (1.36–2.52)** | 94 | **1.95 (1.38–2.41)** |

The model was adjusted for child’s birth year and number of relatives according to type analysis. The model for parents and sibling was also adjusted for mother or father’s education. N, number of cancer cases with relatives affected.
NC, children with <2 relatives diagnosed with cancer estimates were not calculated. We included the ICD-10 codes were we find at least 2 relatives of the index persons diagnosed with cancer.

The bold values mean Hazard ratios statistically significant at 5% level.
ACKNOWLEDGEMENTS

Certain data used in this publication were obtained from the Norwegian Cancer Registry. The authors assume full responsibility for analysis and interpretation of these data. This investigation was supported by a research grant 2016/076902 (Ruby Del Risco Kollerud) from ExtraStiftelsen through the Norwegian Cancer Society, the Research Council of Norway, the Wedel Jarlsberg and Olav Raagholt og Gerd Meidel Raagholt Foundation.

AUTHOR CONTRIBUTIONS

R.D.R.K. designed the study. All authors participated in the data analysis and drafting of the manuscript. All authors also approved the final version of the manuscript to be submitted.

ADDITIONAL INFORMATION

Supplementary information is available for this paper at https://doi.org/10.1383/s41416-019-0445-2.

Competing interests: The authors declare no competing interests.

Ethical approval: The study was performed in accordance with the Declaration of Helsinki. The project was approved by the Regional Committees for Medical and Health Research Ethics (REK Sør-Øst: 2016/1305). As this is a register-linked study, the approval also covers exemption from informed consent because that would not be feasible to acquire.

Data availability: All data generated or analysed during this study are included in this published article and its supplementary information files.

Note: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

REFERENCES

1. Rosen, A., Jayram, G., Drazer, M. & Eggene, S. E. Global trends in testicular cancer incidence and mortality. Eur. J. Cancer, 564, 374–379 (2011).
2. Jacobsen, R., Møller, H., Thoresen, S. Ø., Pukkala, E., Kjaer, S. K. & Johansen, C. Trends in testicular cancer incidence in the Nordic countries, focusing on the recent decrease in Denmark. Int. J. Androl. 29, 199–204 (2006).
3. Williamson, S. R., Delahunt, B., Magi-Galluzzi, C., Algaba, F., Egevad, L., Ulbright, T. M. et al. The World Health Organization 2016 classification of testicular germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel. Histopathology 70, 335–346 (2017).
4. Skakkebaek, N. E., Rajpert-De Meyts, E., Buck Louis, G. M., Toppari, J., Andersson, A. M., Eisenberg, M. L. et al. Male reproductive disorders and fertility trends: influences of environment and genetic susceptibility. Physiol. Rev. 96, 55–97 (2016).
5. Forman, D., Oliver, R. T., Brett, A. R., Marsh, S. G., Moses, J. H., Bodmer, J. G. et al. Familial testicular cancer: a report of the UK family register, estimation of risk and an HLA class 1 sbp-pair analysis. Br. J. Cancer 65, 255–262 (1992).
6. Heimdal, K., Olsson, H., Tretti, S., Flodgren, P., Børresen, A. L. & Fossa, S. D. Familial testicular cancer in Norway and southern Sweden. Br. J. Cancer 72, 964–969 (1996).
7. Spermon, J. R., Witjes, J. A., Nap, M. & Kiemeney, L. A. Cancer incidence in relatives of patients with testicular cancer in the eastern part of The Netherlands. Urol. 57, 747–752 (2001).
8. Nordsborg, R. B., Meliker, J. R., Wohlfahrt, J., Melbye, M. & Raaschou-Nielsen, O. Cancer in first-degree relatives and risk of testicular cancer in Denmark. Int. J. Cancer 129, 2485–2491 (2011).
9. Khanazmi, E., Hemminki, K., Pukkala, E., Sundquist, K., Tryggvadottir, L., Tretti, S. et al. Cancer risk in relatives of testicular cancer patients by histology type and age at diagnosis: A Joint Study from Five Nordic Countries. Eur. J. Cancer 68, 283–289 (2015).
10. Bondj, J. P., Flachs, E. M., Rimborg, S., Glazer, C. H., Giwercman, A., Ramlaug-Hansen, C. H. et al. The epidemiologic evidence linking prenatal and postnatal exposure to endocrine disrupting chemicals with male reproductive disorders: a systematic review and meta-analysis. Hum. Reprod. Update 23, 104–125 (2016).

11. Pukkala, E. & Weiderpass, E. Socio-economic differences in incidence rates of cancers of the male genital organs in Finland, 1971–95. Int. J. Cancer 102, 643–648 (2002).
12. Schneider, K. A. Counseling about Cancer: Strategies for Genetic Counseling 3rd edn. (Wiley-Blackwell, 2011). ISBN: 978-0-470-08150-1.
13. Statistics Norway. Om Seks- og generasjonsdata. http://www.ssb.no/a/mikrodata/datasamlinger/slekt.html
14. Naess, Ø. & Hoff, D. A. The Norwegian Family Based Life Course (NFLC) study: data structure and potential for public health research. Int. J. Public Health 58, 57–64 (2013).
15. World Health Organization. International Classification of Diseases for Oncology 3rd edn, First Revision. (World Health Organization, Geneva, 2013).
16. Berg, J. W. in Cancer Epidemiology and Prevention 2nd edn, eds Shottenfelter, D. & Fraumeni, J., Jr (Oxford University Press, New York, 1996).
17. World Health Organization. International Statistical Classification of Diseases and Related Health Problems 10th revision edn 2010. (World Health Organization, Geneva, 2011). ISBN 9789241548342.
18. Arild Rognan og Nina Barabé. NUS2000, dokumentasjonsrapport (In Norge gian), Statistics Norway, 2001.
19. Zhang, L., Yu, H., Hemminki, Ö., Försti, A., Sundquist, K. & Hemminki, K. Familial associations in testicular cancer with other cancers. Scand. J. Clin. Lab. Invest. 12(3), 363–370 (2004).
20. Stratton, M. R., Campbell, P. J. & Futreal, P. A. The cancer genome. Nature 458, 719–724 (2009).
21. Roach, J. C., Glusman, G., Smit, A. F., Huff, C. D., Hubley, R., Shannon, P. T. et al. Analysis of genetic inheritance in a family quartet by whole-genome sequencing. Science 328, 636–639 (2010).
22. Tuma, M. & Amos, C. Genomic sequencing in cancer. Cancer Lett. 340, 161–170 (2013).
23. Testa, J. R., Cheung, M., Pei, J., Below, D. J., Yan, S., Sementino, E. et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat. Genet. 43, 1022–1025 (2011).
24. Wesner, T., Obenauf, A. C., Murali, R., Fried, I., Grieswank, K. G., Ulls, P. et al. Germline BAP1 mutations in BAP1 predispose to melanocytic tumors. Nat. Genet. 43, 1018–1021 (2011).
25. Popova, T., Hebert, L., Jacquemin, V., Gad, S., Caux-Moncoutier, V., Dubois-d’Énguien, C. et al. Germline BAP1 mutations predispose to renal cell carcinomas. Am. J. Hum. Genet. 92, 974–980 (2013).
26. Rawson, R. V., Watson, G. F., Maher, A. M., McCarthy, S. W., Thompson, J. F. & Scolyer, R. A. Germline BAP1 mutations also predispose to cutaneous squamous cell carcinoma. Pathology 49, 539–542 (2017).
27. Mochel, M. C., Piriis, A., Nose, V. & Hoang, M. P. Loss of BAP1 expression in basal cell carcinomas in patients with germline BAP1 mutations. Am. J. Clin. Pathol. 143, 901–904 (2015).
28. Wadat, K., Aoude, L. G., Johansson, P., Solinas, A., Pritchard, A., Cainen, O. et al. A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma. Clin. Genet. 88, 267–272 (2015).
29. Abdel-Rahman, M. H., Pilarski, R., Celluba, C. M., Massengill, J. B., Christopher, B. N., Boru, G. et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J. Med. Genet. 48, 856–859 (2011).
30. Hoeher, L., Waldschmidt, D., Kuetting, F., Schallenberg, S., Zander, T., Bolschoewier, E. et al. Somatic BRCA1-associated protein 1 (BAP1) loss is an early and rare event in esophageal adenocarcinoma. Mol. Clin. Oncol. 7, 225–228 (2017).
31. Ohr, J. A., Cheung, M., Talarchek, J., Howard, S. E., Howard, T. D., Hesdorpher, M. et al. Germline BAP1 mutational landscape of asbestosexposed malignant mesothelioma patients with family history of cancer. Cancer Res. 76, 206–215 (2016).
32. Shankar, G. M., Abadallahgahi, M., Vaubel, R. A., Merril, P. H., Nayyar, N., Gill, C. M. et al. Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro-oncology 19, 535–545 (2017).
37. McDonnell, K. J., Gallanis, G. T., Heller, K. A., Melas, M., Idos, G. E., Culver, J. O. et al. A novel BAP1 mutation is associated with melanocytic neoplasms and thyroid cancer. *Cancer Genet.* **209**, 75–81 (2016).

38. Carbone, M., Yang, H., Pass, H. I., Krausz, T., Testa, J. R. & Gaudino, G. BAP1 and cancer. *Nat. Rev. Cancer* **13**, 153–159 (2013).

39. Butnor, K. J., Pavlisko, E. N., Sporn, T. A. & Roggli, V. L. Malignant mesothelioma in individuals with nonmesothelial neoplasms. *Arch. Pathol. Lab. Med.* **142**, 730–734 (2018).

40. Soura, E., Eliades, P. J., Shannon, K., Stratigos, A. J. & Tsao, H. Hereditary melanoma: update on syndromes and management: genetics of familial atypical multiple mole melanoma syndrome. *J. Am. Acad. Dermatol.* **74**, 395–407 (2016).

41. Larsen, I. K., Småstuen, M., Johannesen, T. B., Langmark, F., Parkin, D. M., Bray, F. et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. *Eur. J. Cancer* **45**, 1218–1231 (2009).